Read what three clinicians have to say about the current state of diabetes treatment options
.go to activity»
This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
Expiration Date: 12/10/2016
Recent processes have been established to facilitate the production, validation, and utilization of biosimilars. Biosimilars are therapeutic products similar in quality…go to activity»
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Novo Nordisk, Inc.
Expiration Date: 10/1/2016
Obesity has increased dramatically in the past 20 years and is considered a health care epidemic in the United States. According to the US Centers for Disease Control…go to activity»
This activity is supported by an educational grant from Genzyme, a Sanofi company, sanofi-aventis U.S., and Regeneron Pharmaceuticals.
May 20, 2016
This digital monograph, featuring video snippets and key slides from the 2015 CMHC Annual meeting examines current lipid guidelines, the unmet need and residual risk of…go to activity»
This activity is supported by an educational grant from Genentech, Inc.
Expiration Date: 3/10/2017
Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…go to activity»
This activity is supported by an educational grant from Merck & Co., Inc.
December 21, 2015
Patients with type 2 diabetes mellitus are at risk for cardiovascular disease and reducing this risk is a desirable outcome of therapy. Conflicting research on the CV…go to activity»